{"id":61196,"date":"2025-05-03T10:03:49","date_gmt":"2025-05-03T08:03:49","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/tae-life-sciences-and-the-ohio-state-university-forge-landmark-collaboration-to-advance-boron-drug-innovation-for-precision-cancer-therapy\/"},"modified":"2025-05-03T10:03:49","modified_gmt":"2025-05-03T08:03:49","slug":"tae-life-sciences-and-the-ohio-state-university-forge-landmark-collaboration-to-advance-boron-drug-innovation-for-precision-cancer-therapy","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/tae-life-sciences-and-the-ohio-state-university-forge-landmark-collaboration-to-advance-boron-drug-innovation-for-precision-cancer-therapy\/","title":{"rendered":"TAE Life Sciences and The Ohio State University Forge Landmark Collaboration to Advance Boron Drug Innovation for Precision Cancer Therapy"},"content":{"rendered":"
\n

FOOTHILL RANCH, Calif. & COLUMBUS, Ohio–(BUSINESS WIRE)–In a groundbreaking advancement for precision oncology, TAE Life Sciences (TLS) today announced the signing of a Letter of Intent to collaborate with The Ohio State University Comprehensive Cancer Center \u2013 Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC \u2013 James) in the development and evaluation of novel boron-based drug compounds\u2014an essential component of Boron Neutron Capture Therapy (BNCT).\n<\/p>\n

<\/a>
<\/a><\/p>\n

\nThis partnership marks the first-of-its-kind U.S.-based academic-industry alliance dedicated to accelerating BNCT drug innovation and translational research. By optimizing boron delivery agents, TLS and OSUCCC aim to unlock BNCT\u2019s full potential as a powerful, highly selective, and relatively non-toxic therapy and positioning it as a new modality in the next era of precision oncology.\n<\/p>\n

\n\u201cWe are entering a pivotal moment in cancer therapy,\u201d said Dr. Arnab Chakravarti<\/strong>, Chair and Professor of Radiation Oncology, Klotz Family Chair of Cancer Research and Director of the Brain Tumor Program at Ohio State. \u201cBNCT offers an unprecedented opportunity to treat malignancies that are otherwise unresponsive to conventional therapies, while sparing healthy tissue. Our laboratory is uniquely poised to lead this next wave of boron drug innovation, and we are excited to collaborate with TAE Life Sciences in accelerating this effort on a global scale.\u201d\n<\/p>\n

\nThe initial focus of the collaboration will be the preclinical evaluation of TLS\u2019s proprietary boron-10 drugs in cellular and animal models, leveraging Ohio State\u2019s specialized neutron source optimized for BNCT research. In parallel, the teams will pursue joint development of next-generation boron drugs for BNCT and adjacent applications\u2014unlocking new possibilities in precision cancer treatment.\n<\/p>\n

\n\u201cThis partnership marks a major leap forward for the future of BNCT,\u201d said Robert Hill, CEO of TAE Life Sciences. \u201cWe are deeply honored to collaborate with Dr. Chakravarti and his world-class team of research and clinical experts. Their pioneering track record of leadership and innovation will be instrumental not only in advancing the science behind novel boron drug compounds but also in paving the way toward potential regulatory approval. Together, we\u2019re creating a dynamic force for innovation that has the potential to redefine cancer care.\u201d\n<\/p>\n

\nHill notes that this partnership establishes a key pillar for accelerator-based BNCT and significantly accelerate the path to breakthrough cancer therapies, positioning the United States to have a leading position in the next wave of innovation in precision oncology. Hill emphasized that the growing body of international clinical evidence\u2014particularly from Japan, Taiwan, and Europe validates BNCT\u2019s ability to deliver durable responses in patients with otherwise untreatable cancers. This collaboration will help position the United States in having a leading position in advanced drug development and establishing the next wave in precision medicine.\n<\/p>\n

\nAbout TAE Life Sciences<\/b>\n<\/p>\n

\nTAE Life Sciences is a trailblazer in the development of accelerator-based neutron systems and boron-10 drug compounds for Boron Neutron Capture Therapy (BNCT). The company\u2019s mission is to create a highly targeted, minimally invasive cancer therapy platform capable of treating the most resistant tumors with unprecedented precision.\n<\/p>\n

\nAbout The Ohio State University Comprehensive Cancer Center<\/b>\n<\/p>\n

\nThe Ohio State University Comprehensive Cancer Center \u2013 Arthur G. James Cancer Hospital and Richard J. Solove Research Institute strives to create a cancer-free world by integrating scientific research with excellence in education and patient-centered care, a strategy that leads to better methods of prevention, detection, and treatment. Ohio State is one of 54 National Cancer Institute (NCI)-designated Comprehensive Cancer Centers and one of only a few centers funded by the NCI to conduct both phase I and II clinical trials on novel anticancer drugs provided by the NCI. As the cancer program\u2019s 356-bed adult patient-care component, The James is one of the top cancer hospitals in the nation as ranked by U.S. News & World Report and has achieved Magnet\u00ae designation, the highest honor an organization can receive for quality patient care and professional nursing practice. With 21 floors and more than 1.1 million square feet, The James is a transformational facility that fosters collaboration and integration of cancer research and clinical cancer care\n<\/p>\n

Contacts<\/b> <\/p>\n

\nFor more information, please contact:\n<\/p>\n

\nTAE Life Sciences Media Relations
\n
<\/b>email: contact@taelifesciences.com<\/a>
phone: +1 949-830-2117\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

FOOTHILL RANCH, Calif. & COLUMBUS, Ohio–(BUSINESS WIRE)–In a groundbreaking advancement for precision oncology, TAE Life Sciences (TLS) today announced the signing of a Letter of Intent to collaborate with The Ohio State University Comprehensive Cancer Center \u2013 Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC \u2013 James) in the development and … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":["entry","post","publish","author-business","post-61196","format-standard","category-industry"],"yoast_head":"\nTAE Life Sciences and The Ohio State University Forge Landmark Collaboration to Advance Boron Drug Innovation for Precision Cancer Therapy - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/tae-life-sciences-and-the-ohio-state-university-forge-landmark-collaboration-to-advance-boron-drug-innovation-for-precision-cancer-therapy\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"TAE Life Sciences and The Ohio State University Forge Landmark Collaboration to Advance Boron Drug Innovation for Precision Cancer Therapy - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"FOOTHILL RANCH, Calif. & COLUMBUS, Ohio–(BUSINESS WIRE)–In a groundbreaking advancement for precision oncology, TAE Life Sciences (TLS) today announced the signing of a Letter of Intent to collaborate with The Ohio State University Comprehensive Cancer Center \u2013 Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC \u2013 James) in the development and ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/tae-life-sciences-and-the-ohio-state-university-forge-landmark-collaboration-to-advance-boron-drug-innovation-for-precision-cancer-therapy\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2025-05-03T08:03:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20250503894440\/en\/2457443\/22\/TAE-LS-large-sea-and-white.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tae-life-sciences-and-the-ohio-state-university-forge-landmark-collaboration-to-advance-boron-drug-innovation-for-precision-cancer-therapy\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tae-life-sciences-and-the-ohio-state-university-forge-landmark-collaboration-to-advance-boron-drug-innovation-for-precision-cancer-therapy\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"TAE Life Sciences and The Ohio State University Forge Landmark Collaboration to Advance Boron Drug Innovation for Precision Cancer Therapy\",\"datePublished\":\"2025-05-03T08:03:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tae-life-sciences-and-the-ohio-state-university-forge-landmark-collaboration-to-advance-boron-drug-innovation-for-precision-cancer-therapy\\\/\"},\"wordCount\":713,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tae-life-sciences-and-the-ohio-state-university-forge-landmark-collaboration-to-advance-boron-drug-innovation-for-precision-cancer-therapy\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250503894440\\\/en\\\/2457443\\\/22\\\/TAE-LS-large-sea-and-white.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tae-life-sciences-and-the-ohio-state-university-forge-landmark-collaboration-to-advance-boron-drug-innovation-for-precision-cancer-therapy\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tae-life-sciences-and-the-ohio-state-university-forge-landmark-collaboration-to-advance-boron-drug-innovation-for-precision-cancer-therapy\\\/\",\"name\":\"TAE Life Sciences and The Ohio State University Forge Landmark Collaboration to Advance Boron Drug Innovation for Precision Cancer Therapy - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tae-life-sciences-and-the-ohio-state-university-forge-landmark-collaboration-to-advance-boron-drug-innovation-for-precision-cancer-therapy\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tae-life-sciences-and-the-ohio-state-university-forge-landmark-collaboration-to-advance-boron-drug-innovation-for-precision-cancer-therapy\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250503894440\\\/en\\\/2457443\\\/22\\\/TAE-LS-large-sea-and-white.jpg\",\"datePublished\":\"2025-05-03T08:03:49+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tae-life-sciences-and-the-ohio-state-university-forge-landmark-collaboration-to-advance-boron-drug-innovation-for-precision-cancer-therapy\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tae-life-sciences-and-the-ohio-state-university-forge-landmark-collaboration-to-advance-boron-drug-innovation-for-precision-cancer-therapy\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tae-life-sciences-and-the-ohio-state-university-forge-landmark-collaboration-to-advance-boron-drug-innovation-for-precision-cancer-therapy\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250503894440\\\/en\\\/2457443\\\/22\\\/TAE-LS-large-sea-and-white.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250503894440\\\/en\\\/2457443\\\/22\\\/TAE-LS-large-sea-and-white.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tae-life-sciences-and-the-ohio-state-university-forge-landmark-collaboration-to-advance-boron-drug-innovation-for-precision-cancer-therapy\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"TAE Life Sciences and The Ohio State University Forge Landmark Collaboration to Advance Boron Drug Innovation for Precision Cancer Therapy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"TAE Life Sciences and The Ohio State University Forge Landmark Collaboration to Advance Boron Drug Innovation for Precision Cancer Therapy - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/tae-life-sciences-and-the-ohio-state-university-forge-landmark-collaboration-to-advance-boron-drug-innovation-for-precision-cancer-therapy\/","og_locale":"en_US","og_type":"article","og_title":"TAE Life Sciences and The Ohio State University Forge Landmark Collaboration to Advance Boron Drug Innovation for Precision Cancer Therapy - Pharma Trend","og_description":"FOOTHILL RANCH, Calif. & COLUMBUS, Ohio–(BUSINESS WIRE)–In a groundbreaking advancement for precision oncology, TAE Life Sciences (TLS) today announced the signing of a Letter of Intent to collaborate with The Ohio State University Comprehensive Cancer Center \u2013 Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC \u2013 James) in the development and ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/tae-life-sciences-and-the-ohio-state-university-forge-landmark-collaboration-to-advance-boron-drug-innovation-for-precision-cancer-therapy\/","og_site_name":"Pharma Trend","article_published_time":"2025-05-03T08:03:49+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20250503894440\/en\/2457443\/22\/TAE-LS-large-sea-and-white.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/tae-life-sciences-and-the-ohio-state-university-forge-landmark-collaboration-to-advance-boron-drug-innovation-for-precision-cancer-therapy\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/tae-life-sciences-and-the-ohio-state-university-forge-landmark-collaboration-to-advance-boron-drug-innovation-for-precision-cancer-therapy\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"TAE Life Sciences and The Ohio State University Forge Landmark Collaboration to Advance Boron Drug Innovation for Precision Cancer Therapy","datePublished":"2025-05-03T08:03:49+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/tae-life-sciences-and-the-ohio-state-university-forge-landmark-collaboration-to-advance-boron-drug-innovation-for-precision-cancer-therapy\/"},"wordCount":713,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/tae-life-sciences-and-the-ohio-state-university-forge-landmark-collaboration-to-advance-boron-drug-innovation-for-precision-cancer-therapy\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20250503894440\/en\/2457443\/22\/TAE-LS-large-sea-and-white.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/tae-life-sciences-and-the-ohio-state-university-forge-landmark-collaboration-to-advance-boron-drug-innovation-for-precision-cancer-therapy\/","url":"https:\/\/pharma-trend.com\/en\/tae-life-sciences-and-the-ohio-state-university-forge-landmark-collaboration-to-advance-boron-drug-innovation-for-precision-cancer-therapy\/","name":"TAE Life Sciences and The Ohio State University Forge Landmark Collaboration to Advance Boron Drug Innovation for Precision Cancer Therapy - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/tae-life-sciences-and-the-ohio-state-university-forge-landmark-collaboration-to-advance-boron-drug-innovation-for-precision-cancer-therapy\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/tae-life-sciences-and-the-ohio-state-university-forge-landmark-collaboration-to-advance-boron-drug-innovation-for-precision-cancer-therapy\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20250503894440\/en\/2457443\/22\/TAE-LS-large-sea-and-white.jpg","datePublished":"2025-05-03T08:03:49+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/tae-life-sciences-and-the-ohio-state-university-forge-landmark-collaboration-to-advance-boron-drug-innovation-for-precision-cancer-therapy\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/tae-life-sciences-and-the-ohio-state-university-forge-landmark-collaboration-to-advance-boron-drug-innovation-for-precision-cancer-therapy\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/tae-life-sciences-and-the-ohio-state-university-forge-landmark-collaboration-to-advance-boron-drug-innovation-for-precision-cancer-therapy\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20250503894440\/en\/2457443\/22\/TAE-LS-large-sea-and-white.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20250503894440\/en\/2457443\/22\/TAE-LS-large-sea-and-white.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/tae-life-sciences-and-the-ohio-state-university-forge-landmark-collaboration-to-advance-boron-drug-innovation-for-precision-cancer-therapy\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"TAE Life Sciences and The Ohio State University Forge Landmark Collaboration to Advance Boron Drug Innovation for Precision Cancer Therapy"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/61196","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=61196"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/61196\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=61196"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=61196"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=61196"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}